Damage to the brain’s blood vessels accumulates as people age, but scientists still know little about what causes this, much less how to detect or prevent it. A consortium led by scientists at ...

The days when reading a few papers brought scientists up to speed on the developments in their field are gone. Now scientists face mounting volumes of deeply complex datasets, and not remotely enough ...

Affitope AD02 is a synthetic peptide of six amino acids that mimics the N-terminus of Aβ. AFFiRiS hypothesizes that this fragment enables exclusive recognition of Aβ without cross-reacting with APP, ...

Focused ultrasound with microbubbles is a noninvasive procedure that transiently opens the blood-brain barrier (BBB) using low-intensity sound waves. The openings reseal within 24 hours. Using MRI to ...

DZNE maintains a brainbank at five different sites in Germany, at Bonn, Dresden, Munich, Rostock/Greifswald and Tübingen.

The Alzheimer’s field was rocked this week by allegations against Sylvain Lesné at the University of Minnesota, Minneapolis. Lesné stands accused of manipulating data images in multiple papers, ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

Reporting in the August 24 JAMA Neurology online, researchers led by Eric Reiman at Banner Health in Phoenix, confirm what others have suspected from PET imaging, namely, that as many as one-third of ...

Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...

If enhancing memory with light and sound seems futuristic, then welcome to the future. Or so some scientists say. Results from four early stage clinical trials on mild Alzheimer’s disease were ...